Literature DB >> 18552204

Induction of IL-33 expression and activity in central nervous system glia.

Chad A Hudson1, George P Christophi, Ross C Gruber, Joel R Wilmore, David A Lawrence, Paul T Massa.   

Abstract

IL-33 is a novel member of the IL-1 cytokine family and a potent inducer of type 2 immunity, as mast cells and Th2 CD4+ T cells respond to IL-33 with the induction of type 2 cytokines such as IL-13. IL-33 mRNA levels are extremely high in the CNS, and CNS glia possess both subunits of the IL-33R, yet whether IL-33 is produced by and affects CNS glia has not been studied. Here, we demonstrate that pathogen-associated molecular patterns (PAMPs) significantly increase IL-33 mRNA and protein expression in CNS glia. Interestingly, IL-33 was localized to the nucleus of astrocytes. Further, CNS glial and astrocyte-enriched cultures treated with a PAMP followed by an ATP pulse had significantly higher levels of supernatant IL-1beta and IL-33 than cultures receiving any single treatment (PAMP or ATP). Supernatants from PAMP + ATP-treated glia induced the secretion of IL-6, IL-13, and MCP-1 from the MC/9 mast cell line in a manner similar to exogenous recombinant IL-33. Further, IL-33 levels and activity were increased in the brains of mice infected with the neurotropic virus Theiler's murine encephalomyelitis virus. IL-33 also had direct effects on CNS glia, as IL-33 induced various innate immune effectors in CNS glia, and this induction was greatly amplified by IL-33-stimulated mast cells. In conclusion, these results implicate IL-33-producing astrocytes as a potentially critical regulator of innate immune responses in the CNS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552204      PMCID: PMC2516894          DOI: 10.1189/jlb.1207830

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  59 in total

1.  IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils.

Authors:  T Yoshimoto; H Tsutsui; K Tominaga; K Hoshino; H Okamura; S Akira; W E Paul; K Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes.

Authors:  P T Massa; S Saha; C Wu; K W Jarosinski
Journal:  Glia       Date:  2000-02-15       Impact factor: 7.452

3.  IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals.

Authors:  Lien H Ho; Tatsukuni Ohno; Keisuke Oboki; Naoki Kajiwara; Hajime Suto; Motoyasu Iikura; Yoshimichi Okayama; Shizuo Akira; Hirohisa Saito; Stephen J Galli; Susumu Nakae
Journal:  J Leukoc Biol       Date:  2007-09-19       Impact factor: 4.962

Review 4.  The inflammasome in pathogen recognition and inflammation.

Authors:  Fayyaz S Sutterwala; Yasunori Ogura; Richard A Flavell
Journal:  J Leukoc Biol       Date:  2007-04-30       Impact factor: 4.962

5.  Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells.

Authors:  S Matsukura; C Stellato; J R Plitt; C Bickel; K Miura; S N Georas; V Casolaro; R P Schleimer
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

6.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

7.  Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.

Authors:  Thomas Zeis; Ursula Graumann; Richard Reynolds; Nicole Schaeren-Wiemers
Journal:  Brain       Date:  2007-12-04       Impact factor: 13.501

8.  IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice.

Authors:  Waldiceu A Verri; Ana T G Guerrero; Sandra Y Fukada; Daniel A Valerio; Thiago M Cunha; Damo Xu; Sérgio H Ferreira; Foo Y Liew; Fernando Q Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

9.  IL-33, a potent inducer of adaptive immunity to intestinal nematodes.

Authors:  Neil E Humphreys; Damo Xu; Matthew R Hepworth; Foo Y Liew; Richard K Grencis
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

10.  IL-33 reduces the development of atherosclerosis.

Authors:  Ashley M Miller; Damo Xu; Darren L Asquith; Laura Denby; Yubin Li; Naveed Sattar; Andrew H Baker; Iain B McInnes; Foo Y Liew
Journal:  J Exp Med       Date:  2008-02-11       Impact factor: 14.307

View more
  74 in total

Review 1.  Research progress on interleukin-33 and its roles in the central nervous system.

Authors:  Ping Han; Wen-Li Mi; Yan-Qing Wang
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

Review 2.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

3.  Involvement of calcitonin gene-related peptide and CCL2 production in CD40-mediated behavioral hypersensitivity in a model of neuropathic pain.

Authors:  Jennifer T Malon; Swathi Maddula; Harmony Bell; Ling Cao
Journal:  Neuron Glia Biol       Date:  2012-03-01

4.  Borrelia species induce inflammasome activation and IL-17 production through a caspase-1-dependent mechanism.

Authors:  Marije Oosting; Frank L van de Veerdonk; Thirumala-Devi Kanneganti; Patrick Sturm; Ineke Verschueren; Anneleen Berende; Jos W M van der Meer; Bart-Jan Kullberg; Mihai G Netea; Leo A B Joosten
Journal:  Eur J Immunol       Date:  2010-12-09       Impact factor: 5.532

5.  Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts.

Authors:  Jon Sponheim; Jürgen Pollheimer; Trine Olsen; Johanna Balogh; Clara Hammarström; Tamara Loos; Monika Kasprzycka; Dag Reidar Sørensen; Hogne Røed Nilsen; Axel M Küchler; Morten H Vatn; Guttorm Haraldsen
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

6.  The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1.

Authors:  Corinne Cayrol; Jean-Philippe Girard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-13       Impact factor: 11.205

7.  A network map of IL-33 signaling pathway.

Authors:  Sneha M Pinto; Yashwanth Subbannayya; D A B Rex; Rajesh Raju; Oishi Chatterjee; Jayshree Advani; Aneesha Radhakrishnan; T S Keshava Prasad; Mohan R Wani; Akhilesh Pandey
Journal:  J Cell Commun Signal       Date:  2018-04-28       Impact factor: 5.782

8.  IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation.

Authors:  Matthew R Silver; Alexander Margulis; Nancy Wood; Samuel J Goldman; Marion Kasaian; Divya Chaudhary
Journal:  Inflamm Res       Date:  2009-09-18       Impact factor: 4.575

9.  The control of reactive oxygen species production by SHP-1 in oligodendrocytes.

Authors:  Ross C Gruber; Daria LaRocca; Scott B Minchenberg; George P Christophi; Chad A Hudson; Alex K Ray; Bridget Shafit-Zagardo; Paul T Massa
Journal:  Glia       Date:  2015-04-27       Impact factor: 7.452

Review 10.  Disease-associated functions of IL-33: the new kid in the IL-1 family.

Authors:  Foo Y Liew; Nick I Pitman; Iain B McInnes
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.